Evidence map›Paper›PMID 38152700›Full record

ArticleMolecular therapy. Methods & clinical development2023

Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction.

Lucie Poggi, Loïc Chentout, Sabrina Lizot, Alex Boyne, Alexandre Juillerat, Arianna Moiani, Marine Luka, Francesco Carbone, Mickael Ménager, Marina Cavazzana and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Lucie PoggiUniversité de Paris Cité, Imagine Institute, Paris, France.
Loïc ChentoutUniversité de Paris Cité, Imagine Institute, Paris, France.
Sabrina LizotCellectis, 8 rue de la Croix Jarry, 75013 Paris, France.
Alex BoyneCellectis, Inc., 430 East 29th Street, New York, NY 10016, USA.
Alexandre JuilleratCellectis, Inc., 430 East 29th Street, New York, NY 10016, USA.
Arianna MoianiCellectis, 8 rue de la Croix Jarry, 75013 Paris, France.
Marine LukaUniversité de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, 75015 Paris, France.
Francesco CarboneUniversité de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, 75015 Paris, France.
Mickael MénagerUniversité de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, 75015 Paris, France.
Marina CavazzanaUniversité de Paris Cité, Imagine Institute, Paris, France.
Philippe DuchateauCellectis, Inc., 430 East 29th Street, New York, NY 10016, USA.
Julien ValtonCellectis, 8 rue de la Croix Jarry, 75013 Paris, France.
Sven KrackerUniversité de Paris Cité, Imagine Institute, Paris, France.
Cellectis (United States) · USInstitut des Maladies Génétiques Imagine · FRUniversité Paris Cité · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gain-of-function mutations in the

Indexed as

APDS1gene editingPI3K signalingserial killing assaysingle-cell RNA sequencingTALEN

Identifiers

PMID38152700
PMCPMC10751510
OpenAlexW4387496435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.